tiprankstipranks
Trending News
More News >
Charlotte's Web Holdings (TSE:CWEB)
TSX:CWEB
Advertisement

Charlotte's Web Holdings (CWEB) AI Stock Analysis

Compare
180 Followers

Top Page

TSE:CWEB

Charlotte's Web Holdings

(TSX:CWEB)

Select Model
Select Model
Select Model
Neutral 46 (OpenAI - 4o)
Rating:46Neutral
Price Target:
C$0.13
▼(-9.29% Downside)
The overall stock score reflects significant financial challenges, including declining revenues and profitability issues, which are the most impactful factors. Technical analysis indicates weak momentum, and valuation metrics are unattractive due to ongoing losses. However, the earnings call provided some optimism with strategic initiatives and future guidance, slightly improving the outlook.
Positive Factors
Revenue Growth Momentum
Sustained revenue growth indicates successful market penetration and product demand, supporting long-term business expansion and stability.
Innovative Product Launches
Innovative products like Brightside gummies meet consumer demand and diversify revenue streams, enhancing competitive positioning and growth potential.
Cost Optimization and Margin Improvement
Cost-saving initiatives and margin improvements enhance profitability and cash flow, supporting financial health and operational efficiency.
Negative Factors
Rising Debt Levels
Increased leverage heightens financial risk, potentially limiting flexibility and increasing vulnerability to economic downturns.
Negative Cash Flow
Persistent negative cash flow challenges the company's ability to fund operations and invest in growth, impacting long-term viability.
Profitability Issues
Declining margins reflect operational inefficiencies and competitive pressures, which could hinder sustainable profitability and growth.

Charlotte's Web Holdings (CWEB) vs. iShares MSCI Canada ETF (EWC)

Charlotte's Web Holdings Business Overview & Revenue Model

Company DescriptionCharlotte's Web Holdings, Inc. engages in farming, manufacturing, marketing, and selling hemp-derived cannabidiol (CBD) wellness products. The company's products categories include hemp extract oil tinctures, such as liquid products; gummies comprising sleep, stress, immunity, and exercise recovery products; and capsules, CBD topical creams, and lotions, as well as products for pets under the Charlotte's Web, CBD Medic, CBD Clinic, and Harmony Hemp brands. Its products contain naturally occurring phytocannabinoids, including CBD, cannabichromene, cannabigerol, cannabinol, terpenes, flavonoids, and other beneficial hemp compounds. The company distributes its products through retail outlets and health care practitioners, as well as online through its website. It has a collaboration between its CW Labs science division and the University at Buffalo's Center for Integrated Global Biomedical Sciences to advance hemp cannabinoid science through a research program; and scientific collaboration with McLean Hospital. The company was formerly known as Stanley Brothers Holdings Inc. and changed its name to Charlotte's Web Holdings, Inc. in July 2018. Charlotte's Web Holdings, Inc. was founded in 2013 and is headquartered in Denver, Colorado.
How the Company Makes MoneyCharlotte's Web generates revenue primarily through the sale of its CBD products across various channels, including direct-to-consumer sales via its e-commerce platform and retail distribution in health food stores, pharmacies, and other outlets. The company has multiple key revenue streams, including its core product lines like CBD oils, gummies, and topical creams. Additionally, Charlotte's Web has established significant partnerships with retailers and distributors to expand its market reach. Factors contributing to its earnings include the growing consumer demand for CBD products, ongoing product innovation, and a strong brand reputation in the wellness industry.

Charlotte's Web Holdings Earnings Call Summary

Earnings Call Date:Aug 13, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Mar 19, 2026
Earnings Call Sentiment Neutral
Charlotte's Web Holdings demonstrated positive revenue growth and strategic expansion despite facing industry headwinds and regulatory uncertainty. Cost-saving measures and innovative product launches are positioning the company for future profitability, although current financials still reflect challenges with negative EBITDA and net loss.
Q2-2025 Updates
Positive Updates
Revenue Growth Momentum
Achieved a second consecutive quarter of year-over-year revenue growth with net revenue of $12.8 million, representing 4.2% growth from Q2 of last year.
Innovative Product Launches
Successfully launched Brightside low-dose hemp-derived Delta-9 THC gummies, which sold out during Memorial Day weekend, highlighting strong consumer demand.
Cost Optimization and Margin Improvement
Implemented in-house manufacturing for Brightside gummies, expected to yield up to $3 million in annual savings, and reduced SG&A expenses by 31.7% year-over-year.
Positive Regulatory Developments
Promising regulatory developments in the hemp industry could lead to a more favorable market for compliant brands like Charlotte's Web.
Strategic Channel Expansion
Expanded into new digital and specialty channels such as Amazon, TikTok Shop, and Faire, which are delivering incremental revenue.
Negative Updates
Temporary Gross Margin Decline
Gross margin for the quarter was 46.8%, down from the adjusted gross margin of 52.2% in Q2 of last year, due to temporary factors including start-up costs and promotional activities.
Negative EBITDA Performance
Reported adjusted EBITDA loss of $3.5 million, despite a 37.1% improvement over last year's Q2 adjusted EBITDA loss.
Net Loss
Net loss for the quarter was $6.3 million or $0.04 per share, although an improvement from the prior year's net loss of $11.1 million.
Regulatory Uncertainty
The regulatory environment for hemp-derived products remains fluid, which could impact market opportunities.
Company Guidance
During the Charlotte's Web Holdings, Inc. 2025 Second Quarter Conference Call, the company provided guidance reflecting their ongoing transformation and strategic initiatives. They reported a second consecutive quarter of year-over-year revenue growth, with net revenue reaching $12.8 million, marking a 4.2% increase compared to the prior year. The gross profit was $6 million, representing a 46.8% gross margin. Operational improvements include a reduction in SG&A expenses by 31.7% to $10.1 million, partly due to the termination of the MLB promotional rights agreement. The company anticipates $9 million in annualized cost savings by 2026, comprising $6 million from SG&A and $3 million from in-house manufacturing, which is expected to drive significant margin expansion. Additionally, Charlotte's Web is targeting positive cash flow in 2026, supported by these cost reductions and channel optimizations. Their innovative Brightside product line, particularly the low-dose Delta-9 THC gummies, has shown strong market demand, with plans for further product and channel expansion. The company remains optimistic about regulatory developments that could favor established brands in the CBD market.

Charlotte's Web Holdings Financial Statement Overview

Summary
Charlotte's Web Holdings is experiencing significant financial challenges, marked by declining revenues, profitability issues, and increasing financial risk due to higher leverage. Continued negative cash flows and strained margins suggest potential difficulties in sustaining operations without strategic improvements.
Income Statement
45
Neutral
The company has faced declining revenues over the years, with a significant drop in the most recent year. Gross profit margin has also deteriorated from 54% in 2021 to 43% in 2024, indicating pressure on profitability. The net profit margin remained negative, reflecting ongoing losses. Despite efforts, EBIT and EBITDA margins remain negative, indicating operational challenges.
Balance Sheet
50
Neutral
The debt-to-equity ratio increased from 0.09 in 2021 to 2.19 in 2024, suggesting a significant rise in leverage. The equity ratio dropped from 76% in 2021 to 24% in 2024, indicating reduced financial stability. Return on equity remains negative, highlighting profitability issues. The balance sheet reflects increasing financial risk due to higher debt levels.
Cash Flow
40
Negative
Operating cash flow has remained negative, with free cash flow worsening over the period. The free cash flow to net income ratio is negative due to ongoing losses. The operating cash flow to net income ratio is also negative, reflecting cash flow challenges. The company faces difficulties in generating positive cash flow, which could impact its ability to fund operations.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue49.24M49.67M63.16M74.14M96.09M95.23M
Gross Profit21.79M21.26M35.57M19.41M48.59M52.26M
EBITDA-13.60M-22.01M-24.90M-41.68M-38.03M-44.49M
Net Income-21.69M-29.85M-23.80M-59.31M-137.72M-30.68M
Balance Sheet
Total Assets81.60M113.44M152.55M187.64M171.51M310.88M
Cash, Cash Equivalents and Short-Term Investments9.81M22.62M48.99M69.28M20.42M55.55M
Total Debt1.40M59.34M60.44M57.63M22.60M23.36M
Total Liabilities72.35M86.36M96.99M110.14M41.07M56.65M
Stockholders Equity9.25M27.09M55.56M77.50M130.45M254.23M
Cash Flow
Free Cash Flow-14.91M-25.11M-19.08M-5.58M-34.48M-76.85M
Operating Cash Flow-14.04M-21.26M-15.39M-5.32M-29.56M-48.59M
Investing Cash Flow-726.00K-3.80M-3.51M395.00K-11.79M-19.44M
Financing Cash Flow-46.00K-145.00K-251.00K52.39M8.04M55.44M

Charlotte's Web Holdings Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.14
Price Trends
50DMA
0.20
Negative
100DMA
0.16
Negative
200DMA
0.15
Negative
Market Momentum
MACD
-0.02
Negative
RSI
45.13
Neutral
STOCH
52.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CWEB, the sentiment is Negative. The current price of 0.14 is below the 20-day moving average (MA) of 0.15, below the 50-day MA of 0.20, and below the 200-day MA of 0.15, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 45.13 is Neutral, neither overbought nor oversold. The STOCH value of 52.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:CWEB.

Charlotte's Web Holdings Risk Analysis

Charlotte's Web Holdings disclosed 84 risk factors in its most recent earnings report. Charlotte's Web Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Charlotte's Web Holdings Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
51
Neutral
$59.44M-21.73%43.56%-349.41%
48
Neutral
$33.25M183.337.78%28.55%
46
Neutral
$29.44M-0.97-109.83%-4.23%37.33%
46
Neutral
$82.83M-9.90%23.29%33.65%
44
Neutral
C$19.83M-7.43%19.66%84.34%
41
Neutral
$28.86M-18.28-77.67%2.41%74.61%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:CWEB
Charlotte's Web Holdings
0.15
-0.03
-17.14%
TSE:CXXI
C21 Investments
0.45
0.14
45.16%
TSE:ROMJ
Rubicon Organics
0.44
0.05
14.47%
TSE:VEXT
Vext Science
0.22
0.03
15.79%
TSE:AVCN
Avicanna
0.22
-0.13
-37.14%
TSE:GWAY
Greenway Greenhouse Cannabis Corp.
0.17
-0.25
-59.52%

Charlotte's Web Holdings Corporate Events

Charlotte’s Web Holdings Reports Q3 2025 Earnings
Nov 18, 2025

Charlotte’s Web Holdings, Inc., a Certified B Corp headquartered in Louisville, Colorado, operates in the wellness sector, focusing on the production and sale of high-quality hemp-derived products such as CBD oils, gummies, and topicals. The company is engaged in research and development through its CW Labs division, exploring the potential health benefits of hemp-based compounds and other botanical products.

Legal ProceedingsRegulatory Filings and Compliance
ONE HEMP Urges Action Against Federal Hemp Restrictions
Negative
Nov 17, 2025

ONE HEMP is calling for immediate action against new federal hemp restrictions that impose a 0.4 mg total THC limit on full-spectrum CBD products, arguing this limit is unscientific and threatens consumer access to safe wellness products. The coalition is mobilizing efforts to promote science-based regulations that differentiate between legitimate CBD products and harmful synthetics, with legislative solutions being prepared by both the House and Senate to ensure consumer safety and industry innovation.

The most recent analyst rating on (TSE:CWEB) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Charlotte’s Web Holdings stock, see the TSE:CWEB Stock Forecast page.

Business Operations and StrategyFinancial Disclosures
Charlotte’s Web Holdings Reports Strategic Advances in Q3 2025
Positive
Nov 12, 2025

Charlotte’s Web Holdings announced its Q3 2025 results, highlighting strategic transformations aimed at improving performance in 2026. The company has internalized its Brightside™ gummy production, enhancing manufacturing capacity and cost efficiency. A new Scientific Advisory Board has been formed to bolster its medical channel strategy and support its research and development efforts. Additionally, Charlotte’s Web has restructured its B2B retail operations to adapt to regulatory changes, focusing on top revenue-generating customers and building infrastructure for medical practitioners.

The most recent analyst rating on (TSE:CWEB) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Charlotte’s Web Holdings stock, see the TSE:CWEB Stock Forecast page.

Business Operations and StrategyExecutive/Board Changes
Charlotte’s Web Strengthens Board with New Appointment
Positive
Oct 21, 2025

Charlotte’s Web Holdings has appointed M. Borgia Walker to its Board of Directors, effective November 1, 2025. Walker brings three decades of experience in transformation and financial leadership from the global consumer goods and financial services industries. Her expertise in organizational transformation, finance, and regulatory compliance is expected to support Charlotte’s Web’s strategic objectives and enhance its market leadership. This appointment aligns with the company’s values of sustainability and social responsibility, and is seen as a strategic move to strengthen its board and continue its growth trajectory.

The most recent analyst rating on (TSE:CWEB) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Charlotte’s Web Holdings stock, see the TSE:CWEB Stock Forecast page.

Product-Related Announcements
Charlotte’s Web Launches Knockout Sleep Gummies to Expand Hemp Wellness Line
Positive
Oct 14, 2025

Charlotte’s Web Holdings has expanded its Brightside line with the launch of Knockout Hemp THC Sleep Gummies, designed to enhance sleep quality by combining hemp-derived THC and CBN with a rapid-onset delivery system. This new product aims to capture the growing demand for natural sleep solutions, reinforcing the company’s position as a leader in the hemp wellness category and broadening its portfolio of science-backed formulations.

The most recent analyst rating on (TSE:CWEB) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Charlotte’s Web Holdings stock, see the TSE:CWEB Stock Forecast page.

Product-Related Announcements
Charlotte’s Web Expands Sleep Product Line with New Mushroom Gummies
Positive
Sep 30, 2025

Charlotte’s Web Holdings has launched Quiet Sleep Mushroom Gummies, expanding its product line in the sleep and relaxation category. This new melatonin-free and CBD-free product, which combines reishi mushroom, chamomile, and magnesium, addresses consumer demand for natural sleep aids and positions the company to capitalize on the growing functional mushroom and sleep-support markets.

Executive/Board Changes
Charlotte’s Web Holdings Director Resignation Announced
Neutral
Sep 19, 2025

On September 16, 2025, Jonathan Atwood announced his resignation from the Board of Directors at Charlotte’s Web Holdings, effective October 1, 2025. His departure is not due to any disagreements with the company’s operations, policies, or financial practices, indicating a smooth transition without internal conflict.

Business Operations and StrategyExecutive/Board Changes
Charlotte’s Web Forms Scientific Advisory Board to Boost Medical Strategy
Positive
Sep 4, 2025

Charlotte’s Web Holdings, a leader in hemp-derived CBD wellness, has announced the formation of a Scientific Advisory Board to enhance its medical strategy and accelerate research and development efforts. This initiative aims to strengthen the company’s focus on science-backed innovation and expand patient access to plant-based therapeutics. The board will guide clinical initiatives and product formulations, addressing gaps in patient care for conditions like pain and anxiety. Additionally, the company is collaborating with DeFloria, Inc. and Ajna BioSciences PBC on a botanical drug candidate for autism spectrum disorder, which has received FDA approval for Phase 2 clinical trials.

Charlotte’s Web Holdings: Earnings Call Insights
Sep 1, 2025

Charlotte’s Web Holdings’ latest earnings call revealed a cautiously optimistic outlook amidst ongoing challenges. The company demonstrated positive revenue growth and strategic expansion, despite facing industry headwinds and regulatory uncertainty. Cost-saving measures and innovative product launches are positioning the company for future profitability, although current financials still reflect challenges with negative EBITDA and net loss.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 01, 2025